Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 10:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 101 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Alcohol-related Liver Disease Clear all
Completed Phase 2 Interventional Results available

A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis

NCT03432260
View directory record Official record
Conditions
Alcoholic Hepatitis
Interventions
DUR-928 30 mg, DUR-928 90 mg, DUR-928 150 mg
Drug
Lead sponsor
Durect
Industry
Eligibility
21 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
San Diego, California • Miami, Florida • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 8, 2026, 10:09 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy Study of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis

NCT01809132
View directory record Official record
Conditions
Acute Alcoholic Hepatitis
Interventions
Anakinra, Pentoxifylline, Zinc Sulfate, Methylprednisolone
Drug
Lead sponsor
Mack Mitchell
Other
Eligibility
21 Years to 70 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
4
States / cities
Louisville, Kentucky • Worcester, Massachusetts • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 8, 2026, 10:09 AM EDT
Completed Phase 3 Interventional Results available

A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin

NCT01143246
View directory record Official record
Conditions
Hepatorenal Syndrome
Interventions
Terlipressin, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
71
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Oct 8, 2026, 10:09 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Use of F-652 in Patients With Alcoholic Hepatitis

NCT02655510
View directory record Official record
Conditions
Alcoholic Hepatitis
Interventions
F-652
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Oct 8, 2026, 10:09 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Implementation Facilitation Pilot for Alcohol Use Disorder (AUD) in Alcohol-associated Liver Disease (ALD)

NCT07525258
View directory record Official record
Conditions
Alcohol Use Disorder, Alcohol-associated Liver Disease
Interventions
Implementation Intervention
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 8, 2026, 10:09 AM EDT
Completed Phase 2 Interventional Results available

Acamprosate Safe to Use in Individuals With Liver Disease.

NCT04287920
View directory record Official record
Conditions
Alcohol-related Liver Disease
Interventions
Acomprosate
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Oct 8, 2026, 10:09 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effects of SAMe in Patients With Alcoholic Liver Disease

NCT00573313
View directory record Official record
Conditions
Liver Disease, Alcoholic
Interventions
S-adenosylmethionine, Placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
21 Years to 65 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 8, 2026, 10:09 AM EDT
Completed Not applicable Interventional

Implementation of a Digital Clinic for Alcohol-associated Liver Disease and Alcohol Use Disorder (DALC)

NCT06319222
View directory record Official record
Conditions
Alcohol Use Disorder, Liver Diseases
Interventions
DALC Digital Clinic
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 8, 2026, 10:09 AM EDT
Recruiting Phase 2 Interventional

Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

NCT05832229
View directory record Official record
Conditions
Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis Due to Hepatitis C
Interventions
Rosuvastatin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 75 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
13
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 8, 2026, 10:09 AM EDT
Recruiting Phase 2 Interventional

Tirzepatide in MetALD

NCT07046819
View directory record Official record
Conditions
Metabolic Alcohol-associated Liver Disease, Alcohol Use Disorder
Interventions
Tirzepatide, Placebo
Drug · Other
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 100 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 8, 2026, 10:09 AM EDT
Recruiting Not applicable Interventional

Alcohol Treatment Outcomes Following Early vs. Standard Liver Transplant for SAH

NCT03845205
View directory record Official record
Conditions
Alcohol Use Disorder, Alcoholic Hepatitis
Interventions
Integrated AUD Treatment
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 8, 2026, 10:09 AM EDT
Recruiting No phase listed Observational

Hepatic Lipid Metabolism-Alcohol Use Disorder

NCT07191561
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Liver biopsy
Diagnostic Test
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 100 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 8, 2026, 10:09 AM EDT
Completed Phase 2 Interventional Results available

Selonsertib in Combination With Prednisolone Versus Prednisolone Alone in Participants With Severe Alcoholic Hepatitis (AH)

NCT02854631
View directory record Official record
Conditions
Alcoholic Hepatitis (AH)
Interventions
Selonsertib, Prednisolone, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
11
States / cities
Little Rock, Arkansas • Coronado, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 8, 2026, 10:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Zinc Supplementation in Alcoholic Cirrhosis

NCT02072746
View directory record Official record
Conditions
Alcoholic Cirrhosis
Interventions
Zinc, Placebo
Dietary Supplement
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2019
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 22, 2021 · Synced Oct 8, 2026, 10:09 AM EDT
Completed No phase listed Observational

Integrated Approaches for Identifying Molecular Targets in Alcoholic Hepatitis

NCT02075918
View directory record Official record
Conditions
Alcoholic Hepatitis, Control Patients
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 70 Years
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Oct 8, 2026, 10:09 AM EDT
Recruiting Not applicable Interventional

Enhancing Alcohol Treatment Engagement in Associated Liver Disease (ALD) Patients

NCT06269510
View directory record Official record
Conditions
Alcohol-related Liver Disease, Liver Diseases
Interventions
ENGAGE-ALD Application (APP), Treatment Facilitation bundle, Enhanced Usual Care
Behavioral
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 8, 2026, 10:09 AM EDT
Completed Not applicable Interventional Results available

Understanding and Intervening With Heavy Drinking Among Patients With HIV and HCV

NCT03652675
View directory record Official record
Conditions
Alcohol Use Disorder, HIV/AIDS, Hepatitis C, Binge Drinking
Interventions
Intervention: (Clinician's Guide + HealthCall for HIV/HCV)
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 99 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 8, 2026, 10:09 AM EDT
Completed Not applicable Interventional Results available

Computer-based Intervention for Alcohol-using HIV/HCV+ Women

NCT03362476
View directory record Official record
Conditions
Human Immunodeficiency Virus, Hepatitis C, Alcohol Abuse
Interventions
Computer-based alcohol reduction intervention, Brief clinician-delivered MET, Standard of care
Behavioral
Lead sponsor
New York University
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Oct 8, 2026, 10:09 AM EDT
Terminated Phase 2 Interventional Results available

Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF

NCT01937130
View directory record Official record
Conditions
Acute on Chronic Hepatic Failure, Acute Liver Failure, Liver Cirrhosis, Acute Alcoholic Hepatitis
Interventions
IDN-6556, Placebo
Drug · Other
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
11
States / cities
Birmingham, Alabama • La Jolla, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2016 · Synced Oct 8, 2026, 10:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Alcoholic Hepatitis Network Observational Study

NCT03850899
View directory record Official record
Conditions
Alcoholic Hepatitis
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
21 Years and older
Enrollment
1,133 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
9
States / cities
Indianapolis, Indiana • Louisville, Kentucky • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Oct 8, 2026, 10:09 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Phase I, Dose-Escalation Study of Dihydromyricetin (DHM) to Treat Alcohol-Associated Liver Disease

NCT05623501
View directory record Official record
Conditions
Alcohol-Related Disorders
Interventions
Dihydromyricetin
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 8, 2026, 10:09 AM EDT
Completed Phase 2 Interventional

DUR-928 in Patients With Alcoholic Hepatitis

NCT03917407
View directory record Official record
Conditions
Alcoholic Hepatitis
Interventions
DUR-928 (Moderate AH), DUR-928 (Severe AH)
Drug
Lead sponsor
Craig James McClain
Other
Eligibility
21 Years to 67 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Oct 8, 2026, 10:09 AM EDT
Withdrawn No phase listed Observational

Immunology of HIV and Alcoholic Hepatitis

NCT03951662
View directory record Official record
Conditions
HIV/AIDS, Alcoholic Hepatitis
Interventions
Alcoholic Hepatitis Group, Heavy Drinking Controls without Hepatitis
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 8, 2026, 10:09 AM EDT
Terminated Not applicable Interventional Results available

Mild Hypothermia and Acute Kidney Injury in Liver Transplantation

NCT03534141
View directory record Official record
Conditions
Cirrhosis, End Stage Liver Disease, Acute Kidney Injury, Liver Transplant; Complications, Chronic Kidney Diseases, Hepatitis c, Hepatitis B, NASH - Nonalcoholic Steatohepatitis, Alcoholic Cirrhosis, Hepatocellular Carcinoma
Interventions
Esophageal cooling/warming device, Mild hypothermia, Normothermia
Device · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
San Francisco, California • Aurora, Colorado • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 8, 2026, 10:09 AM EDT